Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.
The acquisition strengthens CELLINK’s offering of complete 3D bioprint solutions. The purchase price amounts to MEUR 5 as well as the assumption of net debt in a maximum amount of MEUR 0.4. The purchase price is paid with MEUR 2 in cash and MEUR 3 with CELLINK class B shares (issue in kind to be resolved by CELLINK’s extraordinary general meeting during December 2018).
Vinge’s team primarily consisted of responsible partner Anders Strid, Daniel Lennartsson (M&A) and Alexander Lindeberg (IP). Noerr through, among others, responsible partner Dr. Holger Alfes, acted as local counsel in Germany.
